Turn Therapeutics (NASDAQ:TTRX) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics (NASDAQ:TTRX) to a strong-buy rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other analysts also recently weighed in on TTRX. Wall Street Zen upgraded Turn Therapeutics to a “hold” rating in a report on Saturday. Weiss Ratings upgraded Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Finally, D. Boral Capital reissued a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Trading Up 10.2%

TTRX opened at $10.05 on Monday. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $26.50. The company’s 50 day moving average price is $6.47 and its two-hundred day moving average price is $4.73. The firm has a market capitalization of $299.39 million and a price-to-earnings ratio of -52.89.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Turn Therapeutics

Institutional investors have recently bought and sold shares of the company. Hodges Capital Management Inc. bought a new position in shares of Turn Therapeutics in the 4th quarter worth about $39,000. LPL Financial LLC bought a new stake in shares of Turn Therapeutics during the 4th quarter valued at about $51,000. Tamar Securities LLC acquired a new stake in Turn Therapeutics during the fourth quarter worth approximately $59,000. Composition Wealth LLC bought a new stake in Turn Therapeutics in the fourth quarter worth approximately $63,000. Finally, Geode Capital Management LLC bought a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.